Literature DB >> 26334787

Superselective Chemoembolization of HCC: Comparison of Short-term Safety and Efficacy between Drug-eluting LC Beads, QuadraSpheres, and Conventional Ethiodized Oil Emulsion.

Feng Duan1, Ellen Q Wang1, Marnix G E H Lam1, Mohamed H K Abdelmaksoud1, John D Louie1, Gloria L Hwang1, Nishita Kothary1, William T Kuo1, Lawrence V Hofmann1, Daniel Y Sze1.   

Abstract

PURPOSE: To study the comparative short-term safety and efficacy of transcatheter arterial chemoembolization (TACE) with drug-eluting LC Beads loaded with doxorubicin (DEBDOX), doxorubicin-eluting QuadraSpheres (hqTACE), and conventional TACE using ethiodized oil for superselective C-arm computed tomography (CT)-guided treatment of hepatocellular carcinoma (HCC) after the onset of drug shortages.
MATERIALS AND METHODS: From March 2010 to March 2011, 166 patients with HCC were treated with 232 superselective TACE procedures using C-arm cone-beam CT at one institution. Patients underwent treatment depending on the availability of materials after the onset of drug shortages. Conventional TACE with doxorubicin, cisplatin, and Ethiodol was performed for 159 procedures, DEBDOX TACE was performed for 47, and hqTACE was performed for 26. Toxicity and objective response were compared at 3 months after treatment. Data were stratified for the high-risk population (Child-Pugh class B, performance status 1, bilobar disease, and/or post-resection recurrence) and initial versus repeat treatment. Kruskal-Wallis H test, Mann-Whitney U test, and Fisher exact test were used to compare the groups, with Bonferroni correction where needed.
RESULTS: Whole liver response rates trended higher for conventional TACE (conventional TACE, 65.4%; DEBDOX, 63.8%; hqTACE, 53.8%) (P = .085). Only minor trends for differences in toxicity were observed between the three groups. Low-risk patients had higher whole liver (P = .001) and treated lesion (P = .007) response rates when treated with conventional TACE, but no significant differences were seen for DEBDOX and hqTACE. Treatment-naive patients also had higher whole liver (P = .012) and treated lesion (P = .056) response rates. No advantages for drug-eluting microspheres were found.
CONCLUSION: Within statistical power limitations, overall toxicity and efficacy were equivalent in patients treated with LC Beads, QuadraSpheres, or ethiodized oil emulsions, including in high-risk patients, when performed superselectively with cone-beam C-arm CT guidance. © RSNA, 2015.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26334787     DOI: 10.1148/radiol.2015141417

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  12 in total

1.  Sorafenib Versus Apatinib Both Combined Transarterial Chemoembolization for Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis: A Comparative Retrospective Study.

Authors:  Yanyan Cao; Tao Sun; Xiaopeng Guo; Tao Ouyang; Xuefeng Kan; Lei Chen; Bin Liang; Mingfu Wang; Chuansheng Zheng
Journal:  Front Oncol       Date:  2021-08-03       Impact factor: 6.244

2.  Unresectable hepatocellular carcinoma treatment with doxorubicin-eluting polyethylene glycol microspheres: a single-center experience.

Authors:  Gerardo Tovar-Felice; Andrés García-Gámez; Virgilio Benito-Santamaría; David Balaguer-Paniagua; Jordi Villalba-Auñón; Jaume Sampere-Moragues
Journal:  Hepat Oncol       Date:  2021-06-04

3.  Multibipolar Radiofrequency Ablation for the Treatment of Mass-Forming and Infiltrative Hepatocellular Carcinomas > 5 cm: Long-Term Results.

Authors:  Gisele N'Kontchou; Jean-Charles Nault; Olivier Sutter; Valerie Bourcier; Emmanuelle Coderc; Veronique Grando; Pierre Nahon; Nathalie Ganne-Carrié; Abou Diallo; Nicolas Sellier; Olivier Seror
Journal:  Liver Cancer       Date:  2018-06-28       Impact factor: 11.740

4.  Simultaneous dual-contrast multi-phase liver imaging using spectral photon-counting computed tomography: a proof-of-concept study.

Authors:  Daniela Muenzel; Heiner Daerr; Roland Proksa; Alexander A Fingerle; Felix K Kopp; Philippe Douek; Julia Herzen; Franz Pfeiffer; Ernst J Rummeny; Peter B Noël
Journal:  Eur Radiol Exp       Date:  2017-12-22

5.  Comprehensive Analysis of Factors Affecting Clinical Response and Short-Term Survival to Drug-Eluting Bead Transarterial Chemoembolization for Treatment in Patients With Liver Cancer.

Authors:  Xia Wu; Ran Chen; Weiliang Zheng; Hongjie Hu
Journal:  Technol Cancer Res Treat       Date:  2018-01-01

6.  A novel treatment strategy using indocyanine green for transarterial chemoembolization in BCLC stage C hepatocellular carcinoma.

Authors:  Jie Mei; Shao-Hua Li; Qiao-Xuan Wang; Xiao-Ping Zhong; Liang-He Lu; Anna Kan; Wei Wei; Rong-Ping Guo
Journal:  Cancer Med       Date:  2019-11-08       Impact factor: 4.452

Review 7.  The impacts of medication shortages on patient outcomes: A scoping review.

Authors:  Jonathan Minh Phuong; Jonathan Penm; Betty Chaar; Lachlan Daniel Oldfield; Rebekah Moles
Journal:  PLoS One       Date:  2019-05-03       Impact factor: 3.240

8.  Hepatic fibrosis and short-term clinical efficacy after hepatic artery embolization for unresectable hepatocellular carcinoma using doxorubicin-eluting HepaSphere.

Authors:  Meng Chen; Rongde Xu; Xiaoming Chen; Qicong Mai
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241

9.  Comparison of liver function and safety in hepatocellular cancer patients treated with DEB-TACE and cTACE: a multi-center, retrospective cohort study.

Authors:  Hua Xiang; Bin Xiong; Haiping Li; Chang Zhao; Zishu Zhang; Cong Ma; Chuansheng Zheng; Chao Luo; Huaiming Qiu; Yuanhui Yao; Hongyao Hu; Hui Zhao; Qingyun Long; Jun Zhou; Changyong Chen; Yilong Ma
Journal:  Transl Cancer Res       Date:  2019-09       Impact factor: 1.241

10.  Drug-eluting beads transarterial chemoembolization by CalliSpheres is effective and well tolerated in treating intrahepatic cholangiocarcinoma patients: A preliminary result from CTILC study.

Authors:  Jun Luo; Jiaping Zheng; Changsheng Shi; Jian Fang; Zhiyi Peng; Jing Huang; Junhui Sun; Guanhui Zhou; Tiefeng Li; Dedong Zhu; Huanhai Xu; Qinming Hou; Shihong Ying; Zhichao Sun; Haijun Du; Xiaoxi Xie; Guohong Cao; Wenbin Ji; Jun Han; Wenjiang Gu; Xiaohua Guo; Guoliang Shao; Zhihai Yu; Jian Zhou; Wenqiang Yu; Xin Zhang; Ling Li; Hongjie Hu; Tingyang Hu; Xia Wu; Yutang Chen; Jiansong Ji; Wenhao Hu
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.